Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company aiming to reach breakeven by 2025, with analysts projecting a profit of US$240m in 2026. The company's growth rate is estimated at 64%, indicating confidence in its future success.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing